{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T21:02:51Z","timestamp":1765486971670,"version":"3.37.3"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"(NIAID)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI104681)"],"award-info":[{"award-number":["UM1AI104681)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Antibacterial Resistance Leadership Group (ARLG) has prioritized infections caused by gram-positive bacteria as one of its core areas of emphasis. The ARLG Gram-positive Committee has focused on studies responding to 3 main identified research priorities: (1) investigation of strategies or therapies for infections predominantly caused by gram-positive bacteria, (2) evaluation of the efficacy of novel agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization of dosing and duration of antimicrobial agents for gram-positive infections. Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.<\/jats:p>","DOI":"10.1093\/cid\/ciad565","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T13:59:44Z","timestamp":1697464784000},"page":"S295-S304","source":"Crossref","is-referenced-by-count":5,"title":["Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-6014","authenticated-orcid":false,"given":"Sarah B","family":"Doernberg","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California, SanFrancisco , California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A","family":"Arias","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital , Houston, Texas , USA"},{"name":"Center for Infectious Diseases, Houston Methodist Research Institute , Houston, Texas , USA"},{"name":"Department of Medicine, Weill-Cornell Medical College , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deena R","family":"Altman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine , Icahn School of Medicine at Mount Sinai, New York, New York , USA"},{"name":"Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Babiker","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine , Emory University School of Medicine, Atlanta, Georgia , USA"},{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen W","family":"Boucher","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine , Medford, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C Buddy","family":"Creech","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee , USA"},{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara E","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, George Washington University , Washington, District of Columbia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Vance G","family":"Fowler","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie A","family":"Fritz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimitsu","family":"Hamasaki","sequence":"additional","affiliation":[{"name":"Biostatistics Center, George Washington University , Rockville, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan J","family":"Kelly","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Sixto M","family":"Leal","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Alabama at Birmingham , Birmingham, Alabama , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Liu","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P","family":"Lodise","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences , Albany, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loren G","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles , California , USA"},{"name":"Division of Infectious Diseases, Lundquist Institute at Harbor-UCLA Medical Center , Torrance, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M","family":"Munita","sequence":"additional","affiliation":[{"name":"Instituto de Ciencias e Innovaci\u00f3n en Medicina, Facultad de Medicina Clinica Alemana, Universidad del Desarrollo , Santiago, Chile"},{"name":"Multidisciplinary Initiative for Collaborative Research on Bacterial Resistance , Santiago , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara E","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda M","family":"Pettigrew","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Microbial Diseases, Yale School of Public Health , New Haven, Connecticut , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Ruffin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H","family":"Scheetz","sequence":"additional","affiliation":[{"name":"Pharmacometrics Center of Excellence, College of Pharmacy, Midwestern University , Downers Grove, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Shopsin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine , New York University Grossman School of Medicine, New York, New York , USA"},{"name":"Department of Microbiology, NewYork University Grossman School of Medicine , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truc T","family":"Tran","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, Houston Methodist Research Institute , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas A","family":"Turner","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Pediatrics, Vanderbilt University School of Medicine and the Monroe Carell Jr Children's Hospital at Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smitha","family":"Zaharoff","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L","family":"Holland","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Antibacterial Resistance Leadership Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tori","family":"Kinamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixiao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Geres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancie","family":"Deckard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivra","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrabani","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Wickward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Mehigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varduhi","family":"Ghazaryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Raterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamika","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"2023101612041669900_ciad565-B1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"Suppl_1","key":"2023101612041669900_ciad565-B2","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1093\/cid\/ciw828","article-title":"Gram-positive bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group","volume":"64","author":"Doernberg","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B3","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab616","article-title":"Contemporary clinical and molecular epidemiology of vancomycin-resistant enterococcal bacteremia: a prospective multicenter cohort study (VENOUS I)","volume":"9","author":"Contreras","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023101612041669900_ciad565-B4","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01284-22","article-title":"Multisite detection of Tn1549-mediated vanB vancomycin resistance in multidrug-resistant Enterococcus faecalis ST6 in Texas and Florida","volume":"67","author":"Simar","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612041669900_ciad565-B5","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor's new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B6","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab651","article-title":"Associations between vancomycin exposure and acute kidney injury within the recommended area under the curve therapeutic exposure range among patients with methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"9","author":"Lodise","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023101612041669900_ciad565-B7","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01060-21","article-title":"Of rats and men: a translational model to understand vancomycin pharmacokinetic\/toxicodynamic relationships","volume":"65","author":"Scheetz","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612041669900_ciad565-B8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamapediatrics.2021.5547","article-title":"Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial","volume":"176","author":"Williams","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2023101612041669900_ciad565-B9","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00195-22","article-title":"Comparison of the respiratory resistomes and microbiota in children receiving short versus standard course treatment for community-acquired pneumonia","volume":"13","author":"Pettigrew","year":"2022","journal-title":"mBio"},{"key":"2023101612041669900_ciad565-B10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/infdis\/jiac082","article-title":"Gastrointestinal microbiome disruption and antibiotic-associated diarrhea in children receiving antibiotic therapy for community-acquired pneumonia","volume":"226","author":"Kwon","year":"2022","journal-title":"J Infect Dis"},{"key":"2023101612041669900_ciad565-B11","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic resistance threats in the United States, 2019","author":"Centers for Disease Control and Prevention (CDC)","year":"2019"},{"key":"2023101612041669900_ciad565-B12","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U. S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"key":"2023101612041669900_ciad565-B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/cid\/cir301","article-title":"Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection","volume":"53","author":"Stevens","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41586-022-05438-x","article-title":"Enterococci enhance Clostridioides difficile pathogenesis","volume":"611","author":"Smith","year":"2022","journal-title":"Nature"},{"key":"2023101612041669900_ciad565-B15","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","article-title":"Overdiagnosis of Clostridium difficile infection in the molecular test era","volume":"175","author":"Polage","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2023101612041669900_ciad565-B16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/cid\/ciy539","article-title":"Temporal dynamics and risk factors for bloodstream infection with extended-spectrum \u03b2-lactamase-producing bacteria in previously-colonized individuals: national population-based cohort study","volume":"68","author":"Isendahl","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B17","article-title":"The role of fecal microbiota transplantation in reducing intestinal colonization with antibiotic-resistant organisms: the current landscape and future directions","volume":"6","author":"Woodworth","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023101612041669900_ciad565-B18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw185","article-title":"Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection","volume":"62","author":"Millan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/M18-3635","article-title":"Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics","volume":"171","author":"Ianiro","year":"2019","journal-title":"Ann Intern Med"},{"key":"2023101612041669900_ciad565-B20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41564-021-00966-0","article-title":"Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes","volume":"6","author":"Aggarwala","year":"2021","journal-title":"Nat Microbiol"},{"key":"2023101612041669900_ciad565-B21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41587-020-00797-0","article-title":"Instrain profiles population microdiversity from metagenomic data and sensitively detects shared microbial strains","volume":"39","author":"Olm","year":"2021","journal-title":"Nat Biotechnol"},{"key":"2023101612041669900_ciad565-B22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(21)00007-8","article-title":"The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial","volume":"6","author":"Kao","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023101612041669900_ciad565-B23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"key":"2023101612041669900_ciad565-B24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-27-32","article-title":"Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007","volume":"27","author":"Montazeri","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"2023101612041669900_ciad565-B25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11136-008-9416-4","article-title":"Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses","volume":"18","author":"Garin","year":"2009","journal-title":"Qual Life Res"},{"key":"2023101612041669900_ciad565-B26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cid\/ciaa611","article-title":"Patients\u2019 experiences with Staphylococcus aureus and gram-negative bacterial bloodstream infections: a qualitative descriptive study and concept elicitation phase to inform measurement of patient-reported quality of life","volume":"73","author":"King","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B27","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab622","article-title":"Patients\u2019 experiences with Staphylococcus aureus and gram-negative bacterial bloodstream infections: results from cognitive interviews to inform assessment of health-related quality of life","volume":"9","author":"King","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023101612041669900_ciad565-B28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2023101612041669900_ciad565-B29","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad538","article-title":"The future ain\u2019t what it used to be\u2026out with the old\u2026in with the better: Antibacterial Resistance Leadership Group (ARLG) innovations","volume":"77","author":"Evans","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac190","article-title":"Incidence of monomicrobial Staphylococcus aureus bacteremia: a population-based study in Olmsted County, Minnesota\u20142006 to 2020","volume":"9","author":"Hindy","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023101612041669900_ciad565-B31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2023101612041669900_ciad565-B32","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B33","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/jac\/dkv344","article-title":"Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study","volume":"71","author":"Shrestha","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023101612041669900_ciad565-B34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/cid\/ciac714","article-title":"Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs","volume":"76","author":"Wildenthal","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023101612041669900_ciad565-B36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40121-021-00402-0","article-title":"Safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSI): nephrotoxicity rates compared with vancomycin: a post hoc analysis of three clinical trials","volume":"10","author":"Gonzalez","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2023101612041669900_ciad565-B37","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14740338.2021.1935864","article-title":"Systematic review and meta-analysis on the safety of dalbavancin","volume":"20","author":"Monteagudo-Martinez","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"2023101612041669900_ciad565-B38","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"2023101612041669900_ciad565-B39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B40","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B42","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B43","doi-asserted-by":"crossref","first-page":"106749","DOI":"10.1016\/j.ijantimicag.2023.106749","article-title":"Dalbavancin as sequential therapy for infective endocarditis due to gram-positive organisms: a review","volume":"61","author":"Fazili","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2023101612041669900_ciad565-B44","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab486","article-title":"Multiple-dose dalbavancin regimens as the predominant treatment of deep-seated or endovascular infections: a scoping review","volume":"8","author":"Cooper","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023101612041669900_ciad565-B45","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2023101612041669900_ciad565-B46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","article-title":"Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial","volume":"23","author":"Turner","year":"2022","journal-title":"Trials"},{"key":"2023101612041669900_ciad565-B47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.idc.2020.06.010","article-title":"Applying the infectious diseases literature to people who inject drugs","volume":"34","author":"Serota","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2023101612041669900_ciad565-B48","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/cid\/ciy766","article-title":"Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for Staphylococcus aureus bloodstream infection","volume":"68","author":"Doernberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B49","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023101612041669900_ciad565-B50","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00277-019-03607-z","article-title":"Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases","volume":"98","author":"Weber","year":"2019","journal-title":"Ann Hematol"},{"key":"2023101612041669900_ciad565-B51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13756-018-0419-9","article-title":"The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections","volume":"7","author":"Kramer","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023101612041669900_ciad565-B52","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/cid\/ciz031","article-title":"Bloodstream infection due to vancomycin-resistant Enterococcus is associated with increased mortality after hematopoietic cell transplantation for acute leukemia and myelodysplastic syndrome: a multicenter, retrospective cohort study","volume":"69","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/ice.2015.228","article-title":"VRE and VSE bacteremia outcomes in the era of effective VRE therapy: a systematic review and meta-analysis","volume":"37","author":"Prematunge","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023101612041669900_ciad565-B54","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/tid.12612","article-title":"Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia","volume":"18","author":"Hefazi","year":"2016","journal-title":"Transpl Infect Dis"},{"issue":"Suppl_2","key":"2023101612041669900_ciad565-B55","article-title":"Non-faecium non-faecalis enterococcal bloodstream infections in patients with cancer","volume":"9","author":"Axell-House","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl_2","key":"2023101612041669900_ciad565-B56","article-title":"Association of PBP4 variants and \u03b2-lactam susceptibility in Enterococcus faecalis","volume":"9","author":"Tran","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023101612041669900_ciad565-B57","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612041669900_ciad565-B59","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciaa1744","article-title":"Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus aureus infections: putting the safety of our patients first","volume":"72","author":"Lodise","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B60","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2023101612041669900_ciad565-B61","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B62","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B63","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/526535","article-title":"The Maxwell Finland lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile","volume":"46","author":"Rice","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023101612041669900_ciad565-B64","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/cid\/ciy912","article-title":"Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS)","volume":"68","author":"Evans","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_4\/S295\/52173566\/ciad565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_4\/S295\/52173566\/ciad565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T04:35:57Z","timestamp":1703219757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/Supplement_4\/S295\/7318047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":64,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2023,10,16]]},"published-print":{"date-parts":[[2023,10,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad565","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published-other":{"date-parts":[[2023,10,15]]},"published":{"date-parts":[[2023,10,15]]}}}